Amgen Inc. (NASDAQ: AMGN) declared that the United States (U.S.) Food and Drug Administration (FDA) has authorised Nplate™ (romiplostim), the prototypal and exclusive protoplasm shaper for the communication of thrombopenia in splenectomized (spleen removed) and non-splenectomized adults with habitual insusceptible thrombocytopenic peliosis (ITP).

Tags: ATM, United States